SCHEMBL20161564

SCHEMBL20161564

CNC(=O)CC1O[C@H](CO)[C@@H](OC2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LGALS3 P17931 3/20 0.49
LGALS8 O00214 2/20 0.49
LGALS4 P56470 2/20 0.49
AMY2A P04746 2/20 0.45
IGF2R P11717 2/20 0.45
FGF1 P05230 1/20 0.44
FGF2 P09038 1/20 0.44
VEGFA P15692 1/20 0.44
HPSE Q9Y251 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
AMY1A P0DUB6 1/20 0.44
CA12 O43570 4/20 0.43
CA1 P00915 4/20 0.43
CA2 P00918 4/20 0.43
CA9 Q16790 4/20 0.43
LGALS9 O00182 1/20 0.43
LGALS1 P09382 1/20 0.43
LGALS7; LGALS7B P47929 1/20 0.43
CA14 Q9ULX7 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21342378 1.00 LGALS3 (0.49) LGALS3LGALS8LGALS4AMY2AIGF2R
SCHEMBL22906181 0.85 LGALS3 (0.52) LGALS3LGALS8LGALS4AMY2AIGF2R
SCHEMBL21391458 0.85 LGALS3 (0.52) LGALS3LGALS8LGALS4AMY2AIGF2R
SCHEMBL21391506 0.85 LGALS3 (0.52) LGALS3LGALS8LGALS4AMY2AIGF2R
SCHEMBL21391535 0.85 LGALS3 (0.52) LGALS3LGALS8LGALS4AMY2AIGF2R
SCHEMBL21391497 0.85 LGALS3 (0.52) LGALS3LGALS8LGALS4AMY2AIGF2R
SCHEMBL21391439 0.85 LGALS3 (0.52) LGALS3LGALS8LGALS4AMY2AIGF2R
SCHEMBL22906099 0.85 LGALS3 (0.52) LGALS3LGALS8LGALS4AMY2AIGF2R
SCHEMBL22906100 0.85 LGALS3 (0.52) LGALS3LGALS8LGALS4AMY2AIGF2R
SCHEMBL12080035 0.85 LGALS3 (0.52) LGALS3LGALS8LGALS4AMY2AIGF2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11045411-B2 Process for treating keratin materials using amide, acid or ester c-glycoside derivatives, and cosmetic composition containing same L'OREAL (FR) 2021-06-29 US disclosed
US-20180133137-A1 PROCESS FOR TREATING KERATIN MATERIALS USING AMIDE, ACID OR ESTER C-GLYCOSIDE DERIVATIVES, AND COSMETIC COMPOSITION CONTAINING SAME L'OREAL (FR) 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180133137-A1 PROCESS FOR TREATING KERATIN MATERIALS USING AMIDE, ACID OR ESTER C-GLYCOSIDE DERIVATIVES, AND COSMETIC COMPOSITION CONTAINING SAME KRT18, CUTA, GLA LGALS3 403/4885LGALS8 270/4885LGALS4 351/4885
US-11045411-B2 Process for treating keratin materials using amide, acid or ester c-glycoside derivatives, and cosmetic composition containing same KRT18, CUTA, GLA LGALS3 403/4885LGALS8 270/4885LGALS4 351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.